ELI LILLY AND COMPANY Commercial Paper
ELI LILLY AND COMPANY (LLY) had Commercial Paper of $0 as of 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current
us-gaap:CommercialPaper · last filed 2026-02-12
- 2025-12-31: Commercial Paper $0.00.
- 2024-12-31: Commercial Paper $4.34B; Commercial Paper as first filed $4.34B.
- 2023-12-31: Commercial Paper $6.19B.
- 2022-12-31: Commercial Paper $1.50B.
| Period end | Commercial Paper | Commercial Paper as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-12 | |
| 2024-12-31 | $4.34B 10-K · filed 2026-02-12 | $4.34B 10-K · filed 2025-02-19 |
| 2023-12-31 | $6.19B 10-K · filed 2025-02-19 | |
| 2022-12-31 | $1.50B 10-K · filed 2024-02-21 | |
| 2021-12-31 | $0.00 10-K · filed 2023-02-22 | |
| 2020-12-31 | $0.00 10-K · filed 2021-02-17 | |
| 2019-12-31 | $1.49B 10-K · filed 2021-02-17 | |
| 2018-12-31 | $498.90M 10-K · filed 2020-02-19 | |
| 2017-12-31 | $2.70B 8-K · filed 2019-10-24 | |
| 2016-12-31 | $1.30B 10-K · filed 2018-02-20 | |
| 2015-12-31 | $0.00 10-K · filed 2017-02-21 | |
| 2014-12-31 | $2.68B 10-K · filed 2016-02-19 | |
| 2013-12-31 | $0.00 10-K · filed 2015-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |